title: Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes.
abstract: The objective of this study was to develop a long-term economic model for type 2 diabetes to describe the entire spectrum of the disease over a wide range of healthcare programmes. The model evaluates a public health, risk-based screening programme in a country specific setting.
  
  
  
  The lifespan of persons and important phases of the disease and related interventions are recorded in a Markov model, which first simulates the effect of screening, then replicates important complications of diabetes, follows the progression of individuals through physiological variables and finally calculates outcomes in monetary and naturalistic units.
  
  
  
  The introduction of the screening programme nearly doubled the proportion of diagnosed patients at the age of 50 and prolonged life expectancy. Three-yearly screening gained 0.0229 quality adjusted life years for an additional €83 per person compared with no screening and resulted an incremental cost-effectiveness ratio of €3630/quality adjusted life years.
  
  
  
  From the economic perspective introduction of the 3-yearly screening programme is justifiable and it provides a good value for money. Copyright © 2016 John Wiley & Sons, Ltd.
authors.affiliation: Syreon Research Institute, Budapest, Hungary. balazsnagy@caesar.elte.hu.|Department of Health Policy and Health Economics, Eötvös Loránd University, Budapest, Hungary. balazsnagy@caesar.elte.hu.
authors.forename: Balázs
authors.initials: B
authors.lastname: Nagy
authors.affiliation: Syreon Research Institute, Budapest, Hungary.|Faculty of Social Sciences, Social Policy Ph.D. Programme, Eötvös Loránd University, Budapest, Hungary.
authors.forename: Adriána
authors.initials: A
authors.lastname: Zsólyom
authors.affiliation: Health Sciences Doctoral School, University of Debrecen, Debrecen, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Nagyjánosi
authors.affiliation: Syreon Research Institute, Budapest, Hungary.
authors.forename: Gergő
authors.initials: G
authors.lastname: Merész
authors.affiliation: Faculty of Social Sciences, Social Policy Ph.D. Programme, Eötvös Loránd University, Budapest, Hungary.|2nd Department of Internal Medicine-Diabetology, St. John's Hospital and North-Buda United Institutions, Budapest, Hungary.|Department of Endocrinology, St. Christopher's Clinic, Budapest, Hungary.
authors.forename: Tamás
authors.initials: T
authors.lastname: Steiner
authors.affiliation: National Institute of Pharmacy and Nutrition, Budapest, Hungary.
authors.forename: Eszter
authors.initials: E
authors.lastname: Papp
authors.affiliation: Novartis Hungary, Budapest, Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Dessewffy
authors.affiliation: 3rd Department of Internal Medicine, Bajcsy-Zsilinszky Hospital, Budapest, Hungary.
authors.forename: György
authors.initials: G
authors.lastname: Jermendy
authors.affiliation: 2nd Department of Internal Medicine-Diabetology, St. John's Hospital and North-Buda United Institutions, Budapest, Hungary.|Faculty of Health Care, Institute of Theoretical Sciences, University of Miskolc, Miskolc, Hungary.
authors.forename: Gábor
authors.initials: G
authors.lastname: Winkler
authors.affiliation: Syreon Research Institute, Budapest, Hungary.|Department of Health Policy and Health Economics, Eötvös Loránd University, Budapest, Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kaló
authors.affiliation: Syreon Research Institute, Budapest, Hungary.|Department of Health Policy and Health Economics, Eötvös Loránd University, Budapest, Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Vokó
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008403:Mass Screening / Q000191:economics*; D008875:Middle Aged; D011379:Prognosis; D019057:Quality-Adjusted Life Years; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
keywords: FINDRISC; cost-effectiveness; diabetes; model; patient level simulation; public health intervention; screening